Immunotherapy最新文献_第2页

Evaluating stapokibart in the treatment of seasonal allergic rhinitis. 斯塔波巴特治疗季节性变应性鼻炎的疗效评价。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-03 DOI: 10.1080/1750743X.2025.2554562

Menglin Wang, Jingyun Li, Luo Zhang, Yuan Zhang

引用次数: 0

Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival. 黑素瘤脑转移的治疗模式和结果：探索免疫相关不良事件和生存率。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-25 DOI: 10.1080/1750743X.2025.2548753

Amrita Ladwa, Mu-Hsun Chen, Omar Elghawy, Jacob Friedberg, Hong Zhu, Varinder Kaur

{"title":"Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival.","authors":"Amrita Ladwa, Mu-Hsun Chen, Omar Elghawy, Jacob Friedberg, Hong Zhu, Varinder Kaur","doi":"10.1080/1750743X.2025.2548753","DOIUrl":"10.1080/1750743X.2025.2548753","url":null,"abstract":"Purpose: To investigate real-world treatment patterns, incidence of immune-related adverse events (irAE), and impact of irAEs on outcomes in MBM.Methods: We performed a retrospective study on MBM patients treated with immunotherapy in 2011-2022.Results: Of the 1979 patients treated with immunotherapy, 453 had melanoma and 138 developed MBM. Median time from melanoma diagnosis to CNS metastasis was 37.8 months and median CNS PFS was 11.1 months. Higher burden of MBMs (6-10 or 11+) was associated with worse CNS PFS compared with low MBM burden (1-5 lesions) (HR = 1.89, 95% CI [1.10-3.25]; p = 0.022), (HR = 1.92, 95% CI [1.02-3.63]; p = 0.044). Synchronous MBM (within 30 days of stage IV diagnosis) was associated with improved CNS PFS (HR = 0.65, 95% CI [0.43-0.99]; p = 0.046). Median OS was 22.3 months from development of MBM and 35.0 months from date of first-line therapy for advanced melanoma. All patients received ICI and most (60.1%) developed any grade irAE. Patients who received combination ICI had higher rates of irAE than patients who received single-agent ICI (χ2 = 16.31, p < 0.001). Development of irAE was associated with improved median OS (45.0 months vs 21.7 months, HR = 0.50, 95% CI [0.30-0.83]; p = 0.008).Conclusion: Incidence of irAE was associated with improved survival and trended toward improved CNS PFS.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"801-809"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review. 肝细胞癌患者在阿特唑单抗和贝伐单抗后使用杜伐单抗和tremelimumab：病例报告和文献综述

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-07-28 DOI: 10.1080/1750743X.2025.2539064

Maen Abdelrahim, Abdullah Esmail

{"title":"The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.","authors":"Maen Abdelrahim, Abdullah Esmail","doi":"10.1080/1750743X.2025.2539064","DOIUrl":"10.1080/1750743X.2025.2539064","url":null,"abstract":"Hepatocellular carcinoma (HCC) often presents at an advanced stage, limiting treatment options. Historically, systemic therapies like tyrosine kinase inhibitors and VEGF-targeted antibodies offered modest survival benefits. HCC's immunosuppressive microenvironment, driven by regulatory T cells, myeloid-derived suppressor cells, and immune checkpoint signaling, hinders effective therapy. Immune checkpoint inhibitors (ICPIs) have revolutionized HCC management by targeting these pathways. Atezolizumab and bevacizumab (Atezo/Bev) is the standard first-line therapy for unresectable HCC, but post-progression options are limited. We explore the potential of switching to durvalumab and tremelimumab (Durva/Treme) as a second-line strategy. Recently approved, Durva/Treme shows promise, yet data on sequential ICPI use remain scarce. This editorial highlights the rationale for this approach, leveraging distinct immune targets to overcome resistance. Preliminary evidence suggests durable responses are achievable, but robust clinical trials are needed to validate efficacy, optimize sequencing, and identify biomarkers. Durva/Treme's role as a second-line option could address the critical gap in HCC treatment, challenging the immunosuppressive tumor microenvironment. We advocate for bold innovation to improve outcomes in this complex disease, urging further research into ICPI rechallenge strategies to transform the therapeutic landscape for patients with unresectable HCC.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"783-790"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell and gene therapy in Germany: three decades of advanced technologies. 德国的细胞和基因治疗：三十年的先进技术。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-19 DOI: 10.1080/1750743X.2025.2549241

Amit Sharma, Andreas Neubauer, Burghardt Wittig, Ingo G H Schmidt-Wolf

引用次数: 0

First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap. 中低收入国家转移性NSCLC的一线派姆单抗：弥合疗效差距

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-05 DOI: 10.1080/1750743X.2025.2548754

Ullas Batra, Mansi Sharma, Alexis Andrew Miller, Kundan Singh Chufal, Irfan Ahmad, Abhinav Dewan, Sabeena Chowdhary, B P Amrith, Rashi Sachdeva, Vanshika Batra, Preetha Umesh, Kratika Bhatia, Shrinidhi Nathany, Anurag Mehta, Paulo Nunes Filho, Khaled Tolba, Isagani M Chico, Laura Vidal Boixader, Luca Cantini, Kamal S Saini

{"title":"First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.","authors":"Ullas Batra, Mansi Sharma, Alexis Andrew Miller, Kundan Singh Chufal, Irfan Ahmad, Abhinav Dewan, Sabeena Chowdhary, B P Amrith, Rashi Sachdeva, Vanshika Batra, Preetha Umesh, Kratika Bhatia, Shrinidhi Nathany, Anurag Mehta, Paulo Nunes Filho, Khaled Tolba, Isagani M Chico, Laura Vidal Boixader, Luca Cantini, Kamal S Saini","doi":"10.1080/1750743X.2025.2548754","DOIUrl":"10.1080/1750743X.2025.2548754","url":null,"abstract":"Introduction: Pembrolizumab is a standard first-line therapy for advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking actionable mutations. Data from lower-middle-income countries (LMICs) remain scarce.Methods: From January 2019 to June 2024, we prospectively analyzed 78 a/mNSCLC patients receiving pembrolizumab-based first-line therapy. Endpoints included overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and conditional survival probabilities.Results: With a median follow-up of 27 months, median OS was 21 months (95% CI: 12.2-30.8) and median PFS 6.3 months (95% CI: 5.5-10.1). At first response evaluation (2 months), partial response was seen in 47.4% (37/78), stable disease in 16.7% (13/78). Next-generation sequencing (85% tested) revealed non-actionable mutations in 70%; notably, 4 of 6 long-term survivors harbored KRAS mutations. PD-L1 TPS ≥ 50% significantly lowered progression and mortality risk. Age, performance status (ECOG), and disease response significantly influenced the OS. The conditional survival probability for an additional 6 months after surviving the first 6 months was 78.1% (90% in patients with controlled disease).Conclusion: Real-world LMIC data demonstrated comparable effectiveness of pembrolizumab-based therapy in a/mNSCLC despite a higher proportion of adverse prognostic factors. More studies in diverse clinical settings are needed to provide a reliable estimate of benefit.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"791-800"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study. Amlitelimab，抗ox40配体抗体，用于特应性皮炎：STREAM-AD临床研究的简单语言总结。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-01 DOI: 10.1080/1750743X.2025.2545172

Stephan Weidinger, Andrew Blauvelt, Kim A Papp, Adam Reich, Chih-Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Xiaodan Wei, Wanling Wong, Anne-Catherine Solente, Christine Weber, Samuel Adelman, Sonya Davey, Fabrice Hurbin, Natalie Rynkiewicz, Karl Yen, John T O'Malley, Charlotte Bernigaud

引用次数: 0

A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma. MIRACLE研究的简单语言总结：benralizumab在亚洲严重哮喘患者中的应用

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-11 DOI: 10.1080/1750743X.2025.2550237

Kefang Lai, Dejun Sun, Ranran Dai, Hae-Sim Park, Annika Åstrand, David Cohen, Maria Jison, Vivian H Shih, Viktoria Werkström, Yuhui Yao, Yajuan Zhang, Nanshan Zhong

引用次数: 0

Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature. 以达拉图单抗为基础的方案治疗γ重链疾病：首例病例报告和文献综述

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-08-21 DOI: 10.1080/1750743X.2025.2549673

Carla Cicerchia, Tristan Vaugeois, Nathalie Forgeard, Jean-François Alexandra, Floriane Theves, Stéphanie Harel, Bruno Royer, Sophie Rousselet, Antoine Diep, Patricia Palmic, Bertrand Arnulf, Alexis Talbot

引用次数: 0

Cracking the code: the emerging role of immune checkpoint inhibitors in PEComas. 破解密码：免疫检查点抑制剂在PEComas中的新作用。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-09 DOI: 10.1080/1750743X.2025.2558376

Tarek Assi, Axel Le Cesne

引用次数: 0

Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis. avelumab成功治疗肌萎缩性侧索硬化症患者的局限性Merkel细胞癌。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-08-01 Epub Date: 2025-09-09 DOI: 10.1080/1750743X.2025.2554566

Lisa Arnold, Dirk Tomsitz, Raquel Buchillon, Julia Leding, Sonja Senner, Surina Frey, Nina Janjic, Lars E French, Lucie Heinzerling

引用次数: 0